News Flash!! Once-a-Day Triple NRTI Warning
October 27, 2003
Gilead Sciences, Inc., the manufacturer of the anti-HIV medication Tenofovir (Viread) today issued a "Dear Health Care Professional" letter (click here to view) describing high rates of virologic failure in patients treated with a "once-a-day" triple NRTI regimen that contains: Didanosine (ddI, Videx EC), Lamivudine (3TC, Epivir), and Tenofovir (Viread). This letter is somewhat technical and difficult to understand. Please call Roberto González at 206-957-1659 or 1-888-399-7837 if you would like further explanation.
Quadruple-NRTI Regimen No More Desirable Than Triple-NRTI Regimen in Treatment-Naive Patients, Study Finds
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.